Home
SUPN
SUPN News

Latest Supernus Pharmaceuticals Inc. (SUPN) News on February 23, 2025

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Benzinga

3 days ago

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

MT Newswires

3 days ago

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57

MT Newswires

4 days ago

Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint

Argus Research

4 days ago

SUPN: Raising target price to $42.00

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

GlobeNewswire

4 days ago

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

11 days ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Zacks

16 days ago

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Supernus wins FDA approval for Parkinson’s pump on fourth try

Pharmaceutical Technology

16 days ago

Supernus wins FDA approval for Parkinson’s pump on fourth try

Argus Research

18 days ago

SUPN: Raising target price to $42.00

MT Newswires

18 days ago

Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

GlobeNewswire

18 days ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

7MM PD market to grow by $4.5bn between 2023 and 2033

Clinical Trials Arena

24 days ago

7MM PD market to grow by $4.5bn between 2023 and 2033

Argus Research

25 days ago

SUPN: What does Argus have to say about SUPN?

MT Newswires

a month ago

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

GlobeNewswire

a month ago

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

Argus Research

a month ago

SUPN: Raising target price to $41.00

Argus Research

a month ago

SUPN: Raising target price to $40.00

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

Simply Wall St.

2 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

MT Newswires

2 months ago

Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target

Argus Research

2 months ago

SUPN: Lowering target price to $39.00

Argus Research

2 months ago

SUPN: Rating increased to a BUY

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

GlobeNewswire

2 months ago

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Argus Research

2 months ago

SUPN: What does Argus have to say about SUPN?

Argus Research

3 months ago

SUPN: Raising target price to $39.00

Argus Research

3 months ago

SUPN: Raising target price to $38.00

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

GlobeNewswire

3 months ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

GlobeNewswire

3 months ago

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Argus Research

3 months ago

SUPN: Raising target price to $40.00

MT Newswires

3 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing

MT Newswires

3 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $391,568, According to a Recent SEC Filing

MT Newswires

3 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Argus Research

4 months ago

SUPN: What does Argus have to say about SUPN?

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

4 months ago

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

MT Newswires

4 months ago

Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

4 months ago

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Zacks

4 months ago

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Associated Press Finance

4 months ago

Supernus: Q3 Earnings Snapshot

Supernus Announces Third Quarter 2024 Financial Results

GlobeNewswire

4 months ago

Supernus Announces Third Quarter 2024 Financial Results

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

GlobeNewswire

4 months ago

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

GlobeNewswire

4 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Supernus’ depression drug improved symptoms in two hours in Phase IIa study

Clinical Trials Arena

4 months ago

Supernus’ depression drug improved symptoms in two hours in Phase IIa study

MT Newswires

4 months ago

Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

GlobeNewswire

4 months ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

GlobeNewswire

4 months ago

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

4 months ago

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Argus Research

4 months ago

SUPN: What does Argus have to say about SUPN?

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

GlobeNewswire

5 months ago

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall St.

5 months ago

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire

5 months ago

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug

Insider Monkey

5 months ago

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Benzinga

5 months ago

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Argus Research

6 months ago

SUPN: What does Argus have to say about SUPN?

Argus Research

6 months ago

SUPN: Raising target price to $28.00

MT Newswires

6 months ago

Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

GlobeNewswire

6 months ago

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings

Simply Wall St.

6 months ago

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Zacks

6 months ago

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks

7 months ago

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Zacks

7 months ago

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Associated Press Finance

7 months ago

Supernus: Q2 Earnings Snapshot

Supernus Announces Second Quarter 2024 Financial Results

GlobeNewswire

7 months ago

Supernus Announces Second Quarter 2024 Financial Results

MT Newswires

7 months ago

Supernus Pharmaceuticals Resubmits Marketing Application for Parkinson's Treatment Device

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

GlobeNewswire

7 months ago

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%

Simply Wall St.

7 months ago

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%

Argus Research

7 months ago

SUPN: Raising target price to $24.00

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

GlobeNewswire

7 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Argus Research

7 months ago

SUPN: Raising target price to $23.00

Argus Research

7 months ago

SUPN: What does Argus have to say about SUPN?

VanEck Semiconductor ETF Is Riskier Than You Think

Motley Fool

8 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Motley Fool

8 months ago

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Reuters

8 months ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Simply Wall St.

8 months ago

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

GuruFocus.com

8 months ago

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

GuruFocus.com

8 months ago

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

Insider Sale: Chief Legal Officer Jeff Lendino Sells Shares of Jamf Holding Corp (JAMF)

GuruFocus.com

8 months ago

Insider Sale: Chief Legal Officer Jeff Lendino Sells Shares of Jamf Holding Corp (JAMF)

Insider Sale: President and CEO Kevin Mcnamara Sells Shares of Chemed Corp (CHE)

GuruFocus.com

8 months ago

Insider Sale: President and CEO Kevin Mcnamara Sells Shares of Chemed Corp (CHE)

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

9 months ago

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?

Zacks

9 months ago

Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?

MT Newswires

9 months ago

Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

GlobeNewswire

9 months ago

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

GuruFocus.com

9 months ago

Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...

Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Simply Wall St.

9 months ago

Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

GlobeNewswire

9 months ago

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript

Insider Monkey

9 months ago

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript

GuruFocus.com

9 months ago

Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics

Zacks

9 months ago

Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics

Supernus Announces First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Supernus Announces First Quarter 2024 Financial Results

MT Newswires

10 months ago

Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

PR Newswire

10 months ago

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks

10 months ago

Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

GlobeNewswire

10 months ago

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

GlobeNewswire

10 months ago

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Argus Research

10 months ago

SUPN: What does Argus have to say about SUPN?

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease

Benzinga

10 months ago

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease

Supernus Provides Regulatory Update for SPN-830

GlobeNewswire

10 months ago

Supernus Provides Regulatory Update for SPN-830

Supernus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Supernus to Participate in Two Upcoming Investor Conferences

11 Best Small Cap Pharma Stocks to Invest In

Insider Monkey

a year ago

11 Best Small Cap Pharma Stocks to Invest In

Share on Social Networks: